JPS5944311A - 徐放性顆粒およびその製造法 - Google Patents
徐放性顆粒およびその製造法Info
- Publication number
- JPS5944311A JPS5944311A JP57156073A JP15607382A JPS5944311A JP S5944311 A JPS5944311 A JP S5944311A JP 57156073 A JP57156073 A JP 57156073A JP 15607382 A JP15607382 A JP 15607382A JP S5944311 A JPS5944311 A JP S5944311A
- Authority
- JP
- Japan
- Prior art keywords
- granules
- osmotic pressure
- pressure regulator
- granule
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008187 granular material Substances 0.000 title claims abstract description 75
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 41
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 230000003204 osmotic effect Effects 0.000 claims abstract description 28
- 239000011248 coating agent Substances 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims abstract description 23
- 238000000576 coating method Methods 0.000 claims abstract description 22
- 239000000203 mixture Substances 0.000 claims abstract description 20
- 230000000968 intestinal effect Effects 0.000 claims abstract description 8
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 4
- 150000007524 organic acids Chemical class 0.000 claims abstract 2
- 239000003795 chemical substances by application Substances 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 238000013268 sustained release Methods 0.000 claims description 14
- 239000012730 sustained-release form Substances 0.000 claims description 14
- 230000002496 gastric effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 102000038379 digestive enzymes Human genes 0.000 claims 1
- 108091007734 digestive enzymes Proteins 0.000 claims 1
- 210000004051 gastric juice Anatomy 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract description 19
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract description 18
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 abstract description 8
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 8
- 239000001103 potassium chloride Substances 0.000 abstract description 8
- 235000011164 potassium chloride Nutrition 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 6
- 210000004369 blood Anatomy 0.000 abstract description 6
- -1 etc. Chemical class 0.000 abstract description 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 abstract description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004327 boric acid Substances 0.000 abstract description 2
- 238000000354 decomposition reaction Methods 0.000 abstract description 2
- 150000007522 mineralic acids Chemical class 0.000 abstract description 2
- 230000000087 stabilizing effect Effects 0.000 abstract description 2
- 239000011975 tartaric acid Substances 0.000 abstract description 2
- 235000002906 tartaric acid Nutrition 0.000 abstract description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 abstract 1
- 239000007931 coated granule Substances 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- 239000011230 binding agent Substances 0.000 description 16
- 239000000306 component Substances 0.000 description 16
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 15
- 239000008101 lactose Substances 0.000 description 15
- 239000000843 powder Substances 0.000 description 13
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 12
- 229940126062 Compound A Drugs 0.000 description 11
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 11
- 239000011824 nuclear material Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000013078 crystal Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 239000001087 glyceryl triacetate Substances 0.000 description 6
- 235000013773 glyceryl triacetate Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 229960002622 triacetin Drugs 0.000 description 6
- 229960001270 d- tartaric acid Drugs 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000004014 plasticizer Substances 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 229920003137 Eudragit® S polymer Polymers 0.000 description 4
- 239000008358 core component Substances 0.000 description 4
- 239000011162 core material Substances 0.000 description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000001384 succinic acid Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XTTNKEGJSUXGEK-UHFFFAOYSA-N 2-carbamoyl-3-hydroxybenzoic acid Chemical compound NC(=O)C1=C(O)C=CC=C1C(O)=O XTTNKEGJSUXGEK-UHFFFAOYSA-N 0.000 description 1
- FWNWATHTRVGPDX-UHFFFAOYSA-N 3-(2-methyl-3-sulfanylpropanoyl)-1,3-thiazolidine-4-carboxylic acid Chemical compound SCC(C)C(=O)N1CSCC1C(O)=O FWNWATHTRVGPDX-UHFFFAOYSA-N 0.000 description 1
- SJWSKLANDBKQKV-UHFFFAOYSA-N 3-(3-sulfanylpropanoyl)-1,3-thiazolidine-4-carboxylic acid Chemical compound OC(=O)C1CSCN1C(=O)CCS SJWSKLANDBKQKV-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 235000010005 Catalpa ovata Nutrition 0.000 description 1
- 240000004528 Catalpa ovata Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229920003136 Eudragit® L polymer Polymers 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940075522 antidotes Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- BSHDUMDXSRLRBI-JOYOIKCWSA-N rentiapril Chemical compound SCCC(=O)N1[C@H](C(=O)O)CS[C@@H]1C1=CC=CC=C1O BSHDUMDXSRLRBI-JOYOIKCWSA-N 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57156073A JPS5944311A (ja) | 1982-09-07 | 1982-09-07 | 徐放性顆粒およびその製造法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57156073A JPS5944311A (ja) | 1982-09-07 | 1982-09-07 | 徐放性顆粒およびその製造法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5944311A true JPS5944311A (ja) | 1984-03-12 |
| JPH0260643B2 JPH0260643B2 (enrdf_load_stackoverflow) | 1990-12-17 |
Family
ID=15619707
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57156073A Granted JPS5944311A (ja) | 1982-09-07 | 1982-09-07 | 徐放性顆粒およびその製造法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5944311A (enrdf_load_stackoverflow) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2583638A1 (fr) * | 1985-06-24 | 1986-12-26 | Ciba Geigy Ag | Formes de presentation solides, aptes a la conservation revetues d'une pellicule elastique |
| JPH02138168A (ja) * | 1988-11-18 | 1990-05-28 | Hisamitsu Pharmaceut Co Inc | スルホンアニリド誘導体 |
| US5034417A (en) * | 1987-05-29 | 1991-07-23 | Fujisawa Pharmaceutical Co., Ltd. | New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| US5137733A (en) * | 1990-06-28 | 1992-08-11 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation |
| US5382435A (en) * | 1993-03-24 | 1995-01-17 | Southwest Research Institute | Microparticulate pharmaceutical delivery system |
| JP2003055199A (ja) * | 2001-08-17 | 2003-02-26 | Fujimoto Corporation:Kk | 徐放性マイクロペレット |
| WO2003043661A1 (fr) * | 2001-11-21 | 2003-05-30 | Eisai Co., Ltd. | Compositions de preparation contenant des composes actifs au plan physiologiques et instables aux acides et leur procede de production |
| WO2004066974A1 (en) * | 2003-01-30 | 2004-08-12 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| JP2004525123A (ja) * | 2001-03-08 | 2004-08-19 | ユニジーン・ラボラトリーズ・インコーポレーテッド | 経口ペプチド医薬投与形および製造方法 |
| JP2007524575A (ja) * | 2003-01-30 | 2007-08-30 | エティファーム | 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤 |
| JP2014094939A (ja) * | 2012-10-14 | 2014-05-22 | Tomita Pharmaceutical Co Ltd | 複合核粒子及びそれを含む医薬組成物 |
-
1982
- 1982-09-07 JP JP57156073A patent/JPS5944311A/ja active Granted
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2583638A1 (fr) * | 1985-06-24 | 1986-12-26 | Ciba Geigy Ag | Formes de presentation solides, aptes a la conservation revetues d'une pellicule elastique |
| US5034417A (en) * | 1987-05-29 | 1991-07-23 | Fujisawa Pharmaceutical Co., Ltd. | New alkanesulfonanilide derivatives, processes for preparation thereof and pharmaceutical composition comprising the same |
| JPH02138168A (ja) * | 1988-11-18 | 1990-05-28 | Hisamitsu Pharmaceut Co Inc | スルホンアニリド誘導体 |
| US5137733A (en) * | 1990-06-28 | 1992-08-11 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation |
| US5382435A (en) * | 1993-03-24 | 1995-01-17 | Southwest Research Institute | Microparticulate pharmaceutical delivery system |
| JP2004525123A (ja) * | 2001-03-08 | 2004-08-19 | ユニジーン・ラボラトリーズ・インコーポレーテッド | 経口ペプチド医薬投与形および製造方法 |
| US8512744B2 (en) | 2001-08-17 | 2013-08-20 | Fujimoto Co., Ltd. | Sustained release micropellets and process for producing the same |
| JP2003055199A (ja) * | 2001-08-17 | 2003-02-26 | Fujimoto Corporation:Kk | 徐放性マイクロペレット |
| WO2003015758A1 (fr) * | 2001-08-17 | 2003-02-27 | Fujimoto Co., Ltd. | Micro-pastilles a liberation prolongee et procede permettant leur production |
| WO2003043661A1 (fr) * | 2001-11-21 | 2003-05-30 | Eisai Co., Ltd. | Compositions de preparation contenant des composes actifs au plan physiologiques et instables aux acides et leur procede de production |
| WO2004066974A1 (en) * | 2003-01-30 | 2004-08-12 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| AU2004208512B2 (en) * | 2003-01-30 | 2009-01-29 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| JP4699350B2 (ja) * | 2003-01-30 | 2011-06-08 | エティファーム | 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤 |
| JP2007524575A (ja) * | 2003-01-30 | 2007-08-30 | エティファーム | 味マスキング被覆粒子、その調製方法および前記被覆粒子を含有する口腔内崩壊錠剤 |
| US8663682B2 (en) | 2003-01-30 | 2014-03-04 | Ethypharm | Taste-masking coated particles, process for the preparation thereof and orodispersible tablets containing said coated particles |
| JP2014094939A (ja) * | 2012-10-14 | 2014-05-22 | Tomita Pharmaceutical Co Ltd | 複合核粒子及びそれを含む医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0260643B2 (enrdf_load_stackoverflow) | 1990-12-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960005706B1 (ko) | 경구용 서방성 아세트아미노펜 제형 및 이의 제조방법 | |
| US5126145A (en) | Controlled release tablet containing water soluble medicament | |
| TW420618B (en) | Controlled release-initiation and controlled release-rate pharmaceutical composition | |
| US5211958A (en) | Pharmaceutical composition and process for its preparation | |
| FI77573B (fi) | Ny konsistens. | |
| JPS63162627A (ja) | 徐放性医薬製剤 | |
| JPH05294831A (ja) | 内服用新規医薬製剤 | |
| JP2000514406A (ja) | アルギン酸から成る経口投与製剤用腸溶性被膜 | |
| JPS6345216A (ja) | 持効性処方物 | |
| JPH0122245B2 (enrdf_load_stackoverflow) | ||
| JPS5849312A (ja) | ジピリダモ−ルの経口投与用製剤 | |
| WO1988006457A1 (en) | Medicinal composition containing albumin as carrier and process for its preparation | |
| US4267138A (en) | Coating ensuring a controlled release of active ingredients of biologically active compositions, particularly pharmaceutical compositions and a process for preparation of biologically active compositions ensuring controlled release of active ingredients | |
| JPH06501685A (ja) | 活性物質徐放性を有する溶剤フリーの経口投与すべき医薬製剤およびその製造方法 | |
| US5468503A (en) | Oral pharmaceutical preparation released at infragastrointestinal tract | |
| JPS5944311A (ja) | 徐放性顆粒およびその製造法 | |
| JPS6248618A (ja) | 徐放性製剤およびその製造法 | |
| CA2339942C (en) | Extended release acetaminophen | |
| IE58246B1 (en) | Theophylline sustained release formulation | |
| JPH0428685B2 (enrdf_load_stackoverflow) | ||
| JPS58116414A (ja) | ニカルジピン持続性製剤用球形顆粒およびその製造法 | |
| IE840146L (en) | Pinacidil preparation | |
| JP3833314B2 (ja) | 発泡性組成物およびその製造方法 | |
| TW200918107A (en) | Oral pharmaceutical dosage form and manufacturing method thereof | |
| RU2140272C1 (ru) | Способ получения таблеток натриевой соли фузидовой кислоты без энтеросолюбильного покрытия (варианты), таблетки и гранулят для получения таблеток натриевой соли фузидовой кислоты без энтеросолюбильного покрытия |